Navigation Links
Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
Date:6/29/2009

SOUTHAMPTON, England, June 29 /PRNewswire/ -- Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, announces positive results from a Phase IIa clinical trial of its lead development compound VA106483 for nocturia. The trial showed that oral VA106483 was successful in producing a predictable and sustained anti-diuretic effect in patients, as determined by increased osmolality and decreased urine output. The study also found that VA106483 was generally well tolerated among the patient population.

Nocturia (defined as waking frequently to urinate at night thereby disturbing sleep significantly) is a common condition, with prevalence increasing markedly with age. It is often the presenting symptom in men with benign prostatic hypertrophy (BPH) and affects at least 70% of BPH patients. There is currently no adequate treatment for nocturia and it represents a potential market estimated at more than US$500 million.

VA106483 is a novel small molecule drug candidate that exerts its effect directly in the kidney by binding to vasopressin (V2) receptors, which regulate water balance. It was discovered by Vantia from its extensive drug candidate library.

The double-blind, placebo-controlled, dose-response study was designed to investigate the pharmacodynamics and pharmacokinetics of single and repeated oral doses of VA106483. The trial involved 27 elderly men aged 65 years or more with a history of nocturia.

Based on these results, Vantia now plans to advance VA106483 into a larger Phase IIb clinical efficacy study in the second half of 2009.

Dr Jim Phillips, CEO of Vantia Therapeutics, said 'VA106483 was discovered and has been developed by Vantia based on its small molecule drug development expertise and is the first of several potentially high-value drug candidates in our pipeline. The c
'/>"/>

SOURCE Vantia Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vantia Therapeutics Pipeline Continues to Mature
2. Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
3. Horizon Therapeutics HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
4. InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting
5. Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
6. Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting
7. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
8. FDA Accepts Arno Therapeutics IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
9. Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
10. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
11. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014   Mast Therapeutics, ... company, announced today that Santosh Vetticaden, Chief Medical ... the Company, for personal reasons, in mid-September.  ... Officer of Aires Pharmaceuticals, which Mast acquired earlier ... as the Company,s interim Chief Medical Officer.  Dr. ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Instrument Industry Report, 2014-2017" report to their offering. ... rising proportion of reimbursement for medical expenses, the Chinese ... its scale presenting a CAGR of 19.2% during 2009-2013. ... product segments of orthopedic instruments in China ...
(Date:8/29/2014)... -- Does your doctor know what you,re smoking?  Chances are, ... to the over 112,000 currently registered patients under ... other roughly 20,300+ active physicians listed with the Colorado Dept ... even though a poll in February 2014 showed 51% of ... it. "With marijuana legalization underway, every doctor ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
... DIEGO, March 10 Avineuro Pharmaceuticals, Inc. announced today ... a potent and selective small molecule antagonist of 5-HT6 ... I studies are expected to be available in April ... Inc. plans to advance AVN-211 into Phase II clinical ...
... March 9 What if after 100 years of ... conquest of cancer, a small, unheralded, non-profit organization could ... , , Improbable? Perhaps. Impossible? ... garage revolutionized the computer industry? , , ...
Cached Medicine Technology:Cancer Research 'David' Hopes to Slay 'Cancer Goliath' 2Cancer Research 'David' Hopes to Slay 'Cancer Goliath' 3
(Date:9/1/2014)... News) -- Watching action shows on TV may be bad ... much more snack food while watching action films and programs ... "We find that if you,re watching an action movie ... author Aner Tal, of the Cornell Food and Brand Lab, ... more distracting the program is, the more you will eat." ...
(Date:9/1/2014)... Currently, scientists continue to face fundamental ... disease (AD), which reflects their poor understanding of ... of the disease, especially in its early stages, ... In 2014, after decades that have witnessed ... medicine world, there are still no disease-modifying therapies ...
(Date:9/1/2014)... New York, NY (PRWEB) September 01, 2014 ... filings have been added to a federal litigation that ... of South Carolina, Bernstein Liebhard LLP reports. , ... 1,162 claims now filed over the widely-used cholesterol medication ... to the drug. According to claims, Pfizer Inc. failed ...
(Date:9/1/2014)... The B-cell non-Hodgkin’s Lymphoma (NHL) treatment market value ... US, France, Italy, Germany, Spain and the UK), from ... , The competitive landscape in the B-cell NHL markets ... UK is poised to undergo a dramatic shift during ... B-cell NHL indications, which includes Diffuse Large B-Cell Lymphoma ...
(Date:9/1/2014)... Monday 1 September 2014: Daily fruit consumption cuts ... 40%, according to research presented at ESC Congress today ... from the seven year follow-up study of nearly 0.5 ... the more fruit people ate, the more their risk ... ischaemic heart disease (IHD) and stroke, is the leading ...
Breaking Medicine News(10 mins):Health News:Action-Packed TV a Threat to Your Waistline? 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3
... Get Discount to Switch , ... ... provider of Internet practice management and www.CollaborateMD.com [medical ... program for existing users of Medisoft, Lytec, AltaPoint, Medical Manager ...
... supporters join call for fair & enforceable union,election ground ... is being issued by SEIU United Healthcare Workers - ... System and their supporters,presented an open letter to the ... women religious to help stop the unlawful threats and,intimidation ...
... Minn., Aug. 13 The CHS Foundation,announced today ... the Ralph K.,Morris Foundation,s new Elroy Webster Cooperative ... honorary award to graduate and law,students interested in ... created in memory of Elroy Webster, a,Minnesota farmer ...
... STEN ), a Minneapolis-based diversified business, today reported,results ... June 29,2008. The Company reported a net after-tax ... the third quarter period ended June 29, 2008. ... were $5,035,913, an,increase of 377 percent, or $3,979,309 ...
... cancer,research/programs, DETROIT, Aug. 13 Sean Shearon wanted ... cancer, as well as honor the victims,and survivors of ... 18,marathons in 18 days -- The Victory Walk -- ... programs at the Barbara Ann Karmanos Cancer,Institute, in Detroit. ...
... (August 13, 2008) SAGE, the world,s fifth largest journals ... agreement to publish the Journal of Dental Research ... publication of the International and American Associations for Dental Research ... dedicated to the dissemination of new knowledge and information on ...
Cached Medicine News:Health News:CollaborateMD Offers Upgrade Program to Competitors' Users 2Health News:As Charges Mount, Caregivers and Supporters Call on Sisters of St. Joseph of Orange to Help Stop Unlawful Intimidation of Workers 2Health News:CHS Foundation Helps Launch New Scholarship Fund 2Health News:STEN Corporation Reports 2008 Third-Quarter Revenue of $5 Million and Improved Results From Operations 2Health News:STEN Corporation Reports 2008 Third-Quarter Revenue of $5 Million and Improved Results From Operations 3Health News:STEN Corporation Reports 2008 Third-Quarter Revenue of $5 Million and Improved Results From Operations 4Health News:STEN Corporation Reports 2008 Third-Quarter Revenue of $5 Million and Improved Results From Operations 5Health News:More Than 400-mile Victory Walk to Conclude Aug. 14, at Campus Martius 2Health News:More Than 400-mile Victory Walk to Conclude Aug. 14, at Campus Martius 3Health News:SAGE to publish Journal of Dental Research beginning in 2009 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: